Yan: Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge [Paxlovid]

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Yan et al., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980

Yan et al., Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron.., Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980

Mar 2023 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 195 patients with impaired kidney function in China, showing lower combined mortality/ICU/cardiovascular events, and improved viral clearance with paxlovid.

Confounding by contraindication. [Hoertel] find that over 50% of patients that died had a contraindication for the use of Paxlovid. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.

1. Hoertel et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2022.42140, Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease, https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2798450.

Important missing comments or errors? Let us know.

risk of death, 31.2% lower, RR 0.69, p = 0.50, treatment 7 of 73 (9.6%), control 17 of 122 (13.9%), NNT 23.

mortality/ICU/cardiovascular events, 44.0% lower, HR 0.56, p = 0.04, treatment 73, control 122, adjusted per study, multivariable, model 2, primary outcome.

risk of ICU admission, 13.9% lower, RR 0.86, p = 0.61, treatment 17 of 73 (23.3%), control 33 of 122 (27.0%), NNT 27.

hospitalization time, 8.6% lower, relative time 0.91, p = 0.03, treatment 73, control 122.

time to viral-, 61.5% lower, relative time 0.38, p = 0.001, treatment 73, control 122.

risk of no viral clearance, 73.0% lower, HR 0.27, p < 0.001, treatment 73, control 122, adjusted per study, inverted to make HR<1 favor treatment, viral shedding, multivariable, model 2.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Yan et al., 22 Mar 2023, retrospective, placebo-controlled, China, peer-reviewed, median age 74.0, 10 authors, study period 1 April, 2022 - 30 June, 2022.

Contact: shan_mou@shsmu.edu.cn, guleyi@aliyun.com, monsoon585@foxmail.com.

All Studies All Outcomes Submit Updates or Corrections

This Paper Paxlovid All

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge

Jiayi Yan, Hong Cai, Jieying Wang, Mingli Zhu, Ping Li, Peiying Li, Bin Wu, Xiajing Che, Leyi Gu, Shan Mou

Frontiers in Pharmacology, doi:10.3389/fphar.2023.1147980

Background: Nirmatrelvir/ritonavir has demonstrated effectiveness in high-risk patients with coronavirus disease 2019 . However, investigations on the efficacy and safety of nirmatrelvir/ritonavir in patients with kidney dysfunction are limited. Methods: Data were collected from the patients admitted to a COVID-19 referral center in Shanghai, China. Patients were at least 18 years of age and had a baseline estimated glomerular filtration rate (eGFR) of <60 ml/min/1•73 m 2 . The primary endpoint was a composite of all-cause mortality, intensive care unit admission, or cardiovascular events. The secondary endpoint was viral shedding. Results: Among the 195 participants, 73 received nirmatrelvir/ritonavir. A lower risk of the primary endpoint was observed in nirmatrelvir/ritonavir recipients compared with non-recipients [adjusted HR 0.56 (95% CI: 0.32-0.96); p = 0.035]. Nirmatrelvir/ritonavir recipients experienced a shorter duration of viral shedding ; p < 0.001) and faster viral load clearance versus non-recipients. Among the nirmatrelvir/ritonavir users, earlier initiation of nirmatrelvir/ritonavir within 5 days since COVID-19 diagnosis was related with shorter viral shedding time ; p < 0.001) compared to late initiation. No patients reported serious adverse events during treatment. Conclusion: Our findings support the early initiation of nirmatrelvir/ritonavir for high-risk patients with impaired kidney function. This could improve patient outcomes and shorten the viral shedding period.

Ethics statement The studies involving human participants were reviewed and approved by Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. The ethics committee waived the requirement of written informed consent for participation. Author contributions JY, SM, and LG designed the study. JY, HC, and JW analyzed the data and revised the manuscript. JY and SM drafted and edited the final manuscript. All authors took part in collecting and verifying the Conflict of interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher's note All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher. Supplementary material The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2023.1147980/ full#supplementary-material

References

Arbel, Wolff Sagy, Hoshen, Battat, Lavie et al., Nirmatrelvir use and severe covid-19 outcomes during the omicron surge, N. Engl. J. Med, doi:10.1056/NEJMoa2204919

Carlson, Nelveg-Kristensen, Freese Ballegaard, Feldt-Rasmussen, Hornum et al., Increased vulnerability to COVID-19 in chronic kidney disease, J. Intern Med, doi:10.1111/joim.13239

Christensen, Olsen, Long, Snehal, Davis et al., Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with coronavirus disease 2019 caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in houston, Texas, Am. J. Pathol, doi:10.1016/j.ajpath.2022.01.007

Dejnirattisai, Huo, Zhou, Zahradnik, Supasa et al., None

Gnanenthiran, Borghi, Burger, Caramelli, Charchar et al., Renin-angiotensin system inhibitors in patients with COVID-19: A metaanalysis of randomized controlled trials led by the international society of hypertension, J. Am. Heart Assoc, doi:10.1161/JAHA.122.026143

Graham, Daily briefing: Omicron coronavirus variant puts scientists on alert, Nature, doi:10.1038/d41586-021-03564-6

Hammond, Leister-Tebbe, Gardner, Abreu, Bao et al., Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the US coronavirus disease 2019 (COVID-19)-Associated hospitalization surveillance network (COVID-NET), Nat. Rev. Microbiol, doi:10.1093/cid/ciaa1012

Levey, Stevens, Schmid, Zhang, Castro et al., None

Lingscheid, Kinzig, Kruger, Muller, Bolke et al., Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with endstage renal disease on intermittent hemodialysis, Antimicrob. Agents Chemother

Lu, Zhang, Zhang, Ai, He et al., Geriatric risk and protective factors for serious COVID-19 outcomes among older adults in Shanghai Omicron wave, Emerg. Microbes Infect, doi:10.1080/22221751.2022.2109517

Mahase, Nahhas, Webster, Owen, The promising use of nanomolecular imprinted templates for improved SARS-CoV-2 detection, drug delivery and research, doi:10.1126/science.abl4784

Ozturk, Turgutalp, Arici, Odabas, Altiparmak et al., Mortality analysis of COVID-19 infection in chronic kidney disease, Frontiers in Pharmacology frontiersin

Qiao, Li, Zeng, Liu, Luo et al., SARS-CoV

Russo, Esposito, Taramasso, Magnasco, Saio et al., Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy, J. Nephrol, doi:10.1007/s40620-020-00875-1

Toussi, Neutel, Navarro, Preston, Shi et al., Pharmacokinetics of oral nirmatrelvir/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment, Clin. Pharmacol. Ther, doi:10.1002/cpt.2688

Wang, Peng, Ye, Li, Li et al., Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension, Front. Med, doi:10.1007/s11684-021-0850-9

Zhang, Wang, Ning, He, Wang, Protecting older people: A high priority during the COVID-19 pandemic, Lancet, doi:10.1016/S0140-6736(22)01530-6

Zhang, Zhang, Chen, Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic, Lancet, doi:10.1016/S0140-6736(22)00838-8

Zhang, Zhou ; Flythe, Assimon, Tugman, Chang et al., Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States, doi:10.1002/jmv.27491

Zhu, Xiao, Meng, Tang, Li et al., Nanovesicles derived from bispecific CAR-T cells targeting the spike protein of SARS-CoV-2 for treating COVID-19, J. Nanobiotechnology, doi:10.1186/s12951-021-01148-0

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit